OraSure Q4 revenue record $123.1M (+94% YoY); GAAP EPS $0.21; restructuring cuts 11% of workforce

ORASURE TECHNOLOGIES INC

2022-FY EPS reported -$0.25 revenue$387,479,000

Q4 revenue $123.1M record (+94% YoY); InteliSwab $88.9M (+502% YoY, +12% sequential).
GAAP EPS $0.21, non-GAAP EPS $0.36; full-year GAAP EPS ($0.25), non-GAAP $0.34.
Restructuring combines Molecular & Diagnostics units; 11% non-production role cuts, $15M annual savings by June 2023.
Cash $110.8M, up $9M QoQ; guides Q1 revenue $125–130M (85–92% YoY growth).
New federal InteliSwab contracts through Nov 2023; deal with Quest for saliva collection kits.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ORASURE TECHNOLOGIES INC reported Q4 2022 results: revenue $123,078, net income 15,561, EPS $0.21.

Period: Q4 2022
Revenue: $123,078
Net income: 15,561
EPS: $0.21
Result: reported results

Exact text from the filing

Financial Highlights Three Months Ended Year Ended December 31, December 31, 2022 2021 % Change 2022 2021 % Change Core Diagnostics $ 18,400 $ 17,898 3 % $ 70,007 $ 67,333 4 % InteliSwab 88,857 14,770 502 233,666 22,707 929 Total Diagnostics 107,257 32,668 228 303,673 90,040 237 Core Molecular Solutions 15,684 22,936 (32 ) 74,147 89,467 (17 ) COVID-19 kits 137 7,964 (98 ) 9,659 54,167 (82 ) Total Molecular Solutions 15,821 30,900 (49 ) 83,806 143,634 (42 ) Total Revenue $ 123,078 $ 63,568 94 % $ 387,479 $ 233,674 66 % Three Months Ended Year ended December 31, December 31, 2022 2021 % Change 2022 2021 % Change Net revenues $ 123,078 $ 63,568 94 % $ 387,479 $ 233,674 66 % Gross profit 49,589 27,133 83 147,637 117,600 26 Gross margin 40 % 43 % 38 % 50 % Non-GAAP gross profit 50,126 28,685 75 154,464 121,708 27 Non-GAAP gross margin 41 % 45 % 40 % 52 % Operating income (loss) 13,435 (9,371 ) NM (22,957 ) (10,164 ) NM Operating margin 11 % -15 % -6 % -4 % Non-GAAP operating income (loss) 1

View on SEC.gov

Browse all earnings releases →

ORASURE TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0000950170-23-002800

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.